180 related articles for article (PubMed ID: 14598513)
1. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Grinenko AIa; Krupitskiĭ EM; Zvartau EE
Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
[TBL] [Abstract][Full Text] [Related]
2. [Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].
Krupitskiĭ EM; Zvartau EE; Tsoĭ-Podosenin MV; Masalov DV; Burakov AM; Egorova VIu; Didenko TIu; Romanova TN; Ivanova EB; Bespalov AIu; Verbitskaia EV; Neznanov NG; Grineneko AIa; O'Brien C; Woody D
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 2):44-54. PubMed ID: 21322147
[TBL] [Abstract][Full Text] [Related]
3. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
Adamson SJ; Sellman JD; Foulds JA; Frampton CM; Deering D; Dunn A; Berks J; Nixon L; Cape G
J Clin Psychopharmacol; 2015 Apr; 35(2):143-9. PubMed ID: 25679122
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.
Kranzler HR; Modesto-Lowe V; Van Kirk J
Neuropsychopharmacology; 2000 May; 22(5):493-503. PubMed ID: 10731624
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
J Subst Abuse Treat; 2014; 46(5):546-52. PubMed ID: 24560438
[TBL] [Abstract][Full Text] [Related]
8. Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance.
Gerra G; Zaimovic A; Rustichelli P; Fontanesi B; Zambelli U; Timpano M; Bocchi C; Delsignore R
J Subst Abuse Treat; 2000 Mar; 18(2):185-91. PubMed ID: 10716102
[TBL] [Abstract][Full Text] [Related]
9. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.
Farren CK; Scimeca M; Wu R; Malley SO
Drug Alcohol Depend; 2009 Jan; 99(1-3):317-21. PubMed ID: 18644685
[TBL] [Abstract][Full Text] [Related]
11. A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence.
Farren CK; O'Malley S
Am J Addict; 2002; 11(3):228-34. PubMed ID: 12202015
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
Hulse GK; Ngo HT; Tait RJ
Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
[TBL] [Abstract][Full Text] [Related]
13. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.
Wang AL; Elman I; Lowen SB; Blady SJ; Lynch KG; Hyatt JM; O'Brien CP; Langleben DD
Transl Psychiatry; 2015 Mar; 5(3):e531. PubMed ID: 25781230
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression].
Bun'kova KM
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):29-32. PubMed ID: 18427538
[TBL] [Abstract][Full Text] [Related]
15. Haight-Ashbury free clinics' drug detoxification protocols--Part 2: Opioid blockade.
Galloway G; Hayner G
J Psychoactive Drugs; 1993; 25(3):251-2. PubMed ID: 8258763
[No Abstract] [Full Text] [Related]
16. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
Schottenfeld RS; Chawarski MC; Mazlan M
Lancet; 2008 Jun; 371(9631):2192-200. PubMed ID: 18586174
[TBL] [Abstract][Full Text] [Related]
17. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
18. Clonidine and opiate receptor antagonists in the treatment of heroin addiction.
Gerra G; Marcato A; Caccavari R; Fontanesi B; Delsignore R; Fertonani G; Avanzini P; Rustichelli P; Passeri M
J Subst Abuse Treat; 1995; 12(1):35-41. PubMed ID: 7752296
[TBL] [Abstract][Full Text] [Related]
19. [Depression in alcohol addicted patients].
Ponizovskiy PA; Gofman AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(7):146-150. PubMed ID: 26356528
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.
Lydiard RB; Stahl SM; Hertzman M; Harrison WM
J Clin Psychiatry; 1997 Nov; 58(11):484-91. PubMed ID: 9413414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
